BOSTON, Oct. 28, 2021 /PRNewswire/ -- Today, Ginkgo
Bioworks (NYSE: DNA), the leading horizontal platform for cell
programming, is hosting its annual conference Ferment. The
conference brings together stakeholders from across the synthetic
biology ecosystem and the Ginkgo community, from shareholders and
customers to suppliers, academics, and many more.
The conference will feature a broad array of presentations and
panels throughout the day:
- Welcome Remarks — A keynote from co-founder and CEO
Jason Kelly discussing the power of
biology and Ginkgo's philosophy.
- High Growth, High Stakes: Leadership in Biological
Engineering — A fireside chat between co-founder and
President/COO Reshma Shetty and
Vertex CEO and Ginkgo Board Member Reshma Kewalramani about
leadership of high growth bioengineering companies and the
challenges posed by the pandemic.
- Biosecurity: Preventing the Next Pandemic
— A panel of biosecurity experts moderated by Ginkgo
Vice President of Business Development Renee Wegrzyn, discussing the lessons of
COVID-19 and how to prevent future pandemics, featuring:
-
- Rick Bright, Senior Vice
President of Pandemic Prevention and Response at the Rockefeller
Foundation, who previously served as the Health and Human Services
(HHS) Assistant Secretary for Preparedness and Response and
Director of the Biomedical Advanced R&D Authority (BARDA)
- Scott Gottlieb, the 23rd
Commissioner of the Food and Drug Administration (FDA)
- Brandi Vann, the Deputy
Assistant Secretary of Defense for Chemical and Biological Defense
Programs
- Synthetic Biology and the Cell Therapy Revolution
— Shawdee Eshghi,
Mammalian Program Director at Ginkgo will host a panel discussion
on advancements in cell therapies and the role of synthetic biology
in the future of pharma, with:
-
- Arie Belldegrun, the co-founder and former CEO and Chairman of
Kite Pharma, the co-founder and Chairman of Allogene Therapeutics,
and a Ginkgo Board Member
- David Chang, the co-founder,
President, and CEO of Allogene Therapeutics
- Developing the Next Wave of Products with Synthetic
Biology
-
- Incoming Ginkgo Director of Developer Engagement Jake Wintermute will emcee a round of lightning
talks from developers building products on Ginkgo's platform,
including:
-
- Jasmina Aganovic (CEO,
Arcaea)
- Sasha Calder (Head of
Sustainability, Genomatica)
- Mike Gorenstein (Chairman,
Cronos Group)
- Jon McIntyre (CEO, Motif)
- Nicole Richards (CEO,
Allonnia)
- Michelle Zhu (CEO,
Huue)
- Additionally, Ginkgo's Head of Codebase, Patrick Boyle, will share how developers can
access Ginkgo's platform faster and easier with "cell development
kits" (CDKs), a streamlined offering for customers looking to
technically de-risk projects and get started faster. Starting with
fees as low as $100,000 for protein
expression projects, CDKs are designed to help companies get the
most out of Ginkgo's foundry and codebase quickly and easily.
- How to Predict A Revolution — Michael Specter, staff writer at the New Yorker
and Adjunct Professor of Bioengineering at Stanford University hosts a conversation
between:
-
- Tom Knight, co-founder of Ginkgo
and the "godfather of synthetic biology"
- Cathie Wood, the founder, CEO,
and CIO of ARK Invest, an investment management firm focused on
disruptive innovation
- Biota Beats: The Musical Microbiome of Boston — David Kong, the head of the MIT community biotechnology initiative will present
on the biota beats project, which transforms genetic datasets into
musical compositions.
Videos will be made available to the public following the event,
including on Ginkgo's investor website:
investors.ginkgobioworks.com. Follow @ginkgo on Twitter for
updates.
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program
cells as easily as we can program computers. The company's platform
is enabling biotechnology applications across diverse markets, from
food and agriculture to industrial chemicals to pharmaceuticals.
Ginkgo has also actively supported a number of COVID-19 response
efforts, including K-12 pooled testing, vaccine manufacturing
optimization and therapeutics discovery. For more information,
visit www.ginkgobioworks.com.
Forward-Looking Statements of Ginkgo
Bioworks
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding the potential for developers to access
Ginkgo's platform faster and easier with "cell development kits"
(CDKs) and the potential of Ginkgo's cell programming platform
generally. These forward-looking statements generally are
identified by the words "believe," "can," "project," "potential,"
"expect," "anticipate," "estimate," "intend," "strategy," "future,"
"opportunity," "plan," "may," "should," "will," "would," "will be,"
"will continue," "will likely result," and similar expressions.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
document, including but not limited to: (i) the effect of Ginkgo's
business combination with Soaring Eagle Acquisition Corp. ("Soaring
Eagle") on Ginkgo's business relationships, performance, and
business generally, (ii) risks that the business combination
disrupts current plans of Ginkgo and potential difficulties in
Ginkgo's employee retention, (iii) the outcome of any legal
proceedings that may be instituted against Ginkgo related to its
business combination with Soaring Eagle, (iv) volatility in the
price of Ginkgo's securities now that it is a public company due to
a variety of factors, including changes in the competitive and
highly regulated industries in which Ginkgo plans to operate,
variations in performance across competitors, changes in laws and
regulations affecting Ginkgo's business and changes in the combined
capital structure, (v) the ability to implement business plans,
forecasts, and other expectations after the completion of the
business combination, and identify and realize additional
opportunities, and (vi) the risk of downturns in demand for
products using synthetic biology. The foregoing list of factors is
not exhaustive. You should carefully consider the foregoing factors
and the other risks and uncertainties described in the "Risk
Factors" section of Ginkgo's current report on Form 8-K filed with
the U.S. Securities and Exchange Commission (the "SEC") on
September 20, 2021 and other
documents filed by Ginkgo from time to time with the SEC. These
filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Ginkgo assumes no obligation and does not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Ginkgo does
not give any assurance that it will achieve its expectations.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
investors@ginkgobioworks.com
MEDIA CONTACT:
press@ginkgobioworks.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-previews-todays-annual-ferment-conference-301410927.html
SOURCE Ginkgo Bioworks